Move a drug program forward
Compare candidates, doses and combinations across efficacy, safety, mechanism and biomarker readouts.
Explore relevant study options ↗HUMAN ORGANOIDS · PDO 2.0 / ALI
Human organoids for drug discovery and development.
Advance target discovery, efficacy and safety studies with human organoids. For immuno-oncology, PDO 2.0 / ALI brings tumor architecture and sample-derived immune cells into treatment-response studies.
HUMAN ORGANOID RESEARCH PLATFORMImmune context & ADC · normal-tissue safety · disease models
- ORGANOID CULTURE · BRIGHT-FIELD：Bright-field morphology of an organoid culture
- PDO 2.0 · TISSUE & IMMUNE CONTEXT：Histology, epithelial and immune markers in colorectal source tissue and PDO 2.0
- ANTIBODY & NANOBODY · SECTION DISTRIBUTION：Relative spatial distribution of labeled antibody and nanobody in organoid frozen sections
- HUMAN NORMAL KIDNEY ORGANOIDS：Whole-organoid and local morphology of human normal kidney organoids
- NORMAL LUNG ORGANOIDS · AIRWAY LINEAGE：Merged SCGB1A1 (CC10) and KRT5 airway-lineage fluorescence image in normal lung organoids
- ADJACENT NON-TUMOR LIVER ORGANOIDS：Day 8 morphology of organoids from adjacent non-tumor liver tissue
- MESENCHYMAL TUMOR · PDO MORPHOLOGY：Source tissue, cultured organoid bright-field and cultured histology in a patient-derived mesenchymal tumor model
- BBB-RELATED CO-CULTURE · ZO-1 JUNCTIONS：Focused ZO-1 junction image in a BBB-related co-culture system
- GBM PDO 2.0 · HISTOLOGY & LINEAGE：Histology and lineage markers in GBM tumor tissue and PDO 2.0
01HUMAN SAMPLES02MODELS & READOUTS03R&D DECISIONS
01PDO 2.0 / ALITissue architecture & immune cells retained from the source sample
02PEER-REVIEWED SCIENCEALI and tumor–immune organoid research involving our Chief Scientist, published in Nature Medicine and Cell
03STUDY DESIGNModels and assays matched to your development objective
04Nanjing · Shanghai · PhiladelphiaChina R&D · global project coordination
Why TRiCBIO
Built around your research question
Scientific expertise, complementary models and integrated assays—from study design to interpretable results.
01ALI research · Nature Medicine · Cell
The science behind PDO 2.0 / ALI
ALI research in Nature Medicine and tumor–immune organoid work in Cell, involving TRiCBIO’s Chief Scientist, guide our PDO 2.0 platform and study design.
Explore PDO 2.0 02Model · assay · analysis · deliveryFrom model to R&D decision
Connect model characterization, functional assays and molecular analysis in one study, with results and documentation ready for your team to review.
Explore the technology 03Selected models · documented assays · flexible collaborationTumor, normal-tissue and disease models
Combine tumor PDOs, normal-tissue organoids and disease models to evaluate efficacy, mechanism and organ-specific safety within a connected research program.
Browse models 04Scientific team involvementScientists engaged in your program
Work with scientists experienced in target discovery, functional genomics, clinical pharmacology and drug development to shape the model, assays and next steps.
Meet the scientific teamWhat are you working on?
Match the model and study to your objective
Choose contract research, model development or scientific collaboration to fit your program.
Disease models & scientific collaboration
Develop clinical-sample organoids and disease models for functional validation, method development and collaborative research.
Explore relevant study options ↗Explore study options
Start with your study goal
Enter by study goal, therapeutic modality or model system, then continue to the relevant services, models and case studies.
Explore your research focus
Explore models and case studies for target discovery, candidate comparison, safety and immune research.
01
Target discovery & functional genomics
Connect library screening, gene-dependency discovery and functional validation across PDO 1.0 and PDO 2.0.
Explore target-discovery services 02Candidate comparison
Compare efficacy, dose, combinations and response differences across models.
Explore the study approach 03Safety & toxicology
Build a safety study around organ injury and exposure conditions.
Explore the study approach 04Immune microenvironment
Relate tissue context and immune components to treatment response.
Explore the study approachHow does the candidate work?
Different modalities call for different models, controls and readouts.
01
Small molecules & targeted agents
Compare dose, timing, combinations and mechanism-focused endpoints.
Explore the application 02Antibodies, multispecifics & TCEs
Examine target expression, effector context and dynamic killing together.
Explore the application 03ADCs
Study target heterogeneity, tissue spatial distribution and cytotoxicity.
Explore the application 04Immunotherapy
Combine PDO 2.0 / ALI with program-relevant immune readouts.
Explore the applicationChoose the biological context your study needs
Start with tumor, normal-tissue or disease models, then connect the right model and assays to the next stage of your program.
01
Tumor PDO & PDO 2.0
Choose by cancer, tissue context and need for immune information.
Browse relevant models 02Non-tumor organ models
Normal-tissue, adjacent non-tumor and stem-cell-derived models for tissue phenotypes, injury and organ-specific safety.
Browse relevant models 03Disease models
Study inflammation, barrier, cyst and disease-associated phenotypes.
Browse relevant models 04Custom & co-development
Develop specialized models, co-cultures and functional assays around the study goal.
Explore custom collaborationPDO 2.0 / ALI
Bring tumor and immune biology into focus
PDO 2.0 uses an air–liquid interface to study treatment response alongside source-tissue architecture and immune cells retained from the original sample. It supports tumor-microenvironment profiling, immunotherapy and combination studies.
See how PDO 2.0 works01Tissue architecture and tumor-cell profilingH&E · IF · IHC
02Sample-derived immune-context profilingFACS · TCR · Cytokines
03Integrated histology, flow and functional analysisViability · Barrier · Response
TRiCBIO BIOBANK
Organoid model resources
Find models for your research and request PDO line availability, characterization and study data from our scientific team.
Tumor organoids
Match cancer type and research context for target validation and drug-response studies.
Explore model ↗
PDO 2.0 / ALI
Explore microenvironment-associated mechanisms and treatment response in tissue and immune context.
Explore model ↗
Normal-tissue organoids
Study tissue function and injury responses for safety and selectivity research.
Explore model ↗Featured models & study results
Explore models. See the results.
Explore representative models alongside microscopy, molecular profiling and treatment-response data.
01
Featured model optionsChoose by model type and study context
Swipe or use arrow keys to explore more models
Tumor PDO 2.0
An ALI-based tumor model for studying treatment response alongside source-tissue architecture and immune cells retained from the sample.
Model details & study areas ↗
Human kidney organoids
Assess drug-related kidney injury through morphology, nephron markers and molecular readouts, with culture conditions matched to your candidate.
Model details & study areas ↗
Human intestinal organoid IBD-like inflammation model
Study IBD-like inflammation in human intestinal organoids through morphology, FITC-Dextran, IL-8 and image-based candidate readouts.
Model details & study areas ↗02
Study resultsExplore model characterization, readouts and study findings
Swipe or use arrow keys to explore more study results
Immune signals and treatment response in PDO 2.0
Select histology, cell-death and T-cell profiling endpoints for immunotherapy studies across different sample contexts.
View study results ↗
Antibody distribution and ADC response in breast PDOs
Plan ADC imaging, dose selection and candidate comparisons using labeled-antibody/nanobody distribution and ADC activity readouts.
View study results ↗
Normal lung and kidney organoids for safety studies
Select a lung, kidney or dual-organ strategy with safety endpoints matched to the candidate's risk profile.
View study results ↗More models and custom studies
Explore the full portfolio or discuss a custom study
Tumor PDO / PDO 2.0Normal kidney · lung · stomach + adjacent non-tumor liverHuman IBD-like inflammation study · tailored ADPKD/BBB studiesMulti-organ safetySpecialized tissue & co-culture studies
Apply these capabilities to your study
Match models and assays ↗Tell us your candidate, research priorities and available samples. We will recommend models, initial assays and expected deliverables.
How we work
Four steps to project delivery
From an initial scientific discussion to an agreed study plan, experimental work and results your team can use.
Project goal
Clarify the objective and priority endpoints
Plan and quote
Confirm the model, assays and study scope
Study and analysis
Run the study and integrate the data
Results and next step
Review the results and agree on the next study step
News & Events
Meet us. Explore what comes next.
MEET TRiCBIO
Human tumor–immune biology
Phoenix, Arizona
Phoenix, Arizona
SITC 2026: Let's talk human tumor–immune biology
Connect with TRiCBIO to discuss PDO 2.0, immunotherapy and combination studies.
Read more ↗TRiCBIO · HONG KONG ROADSHOW
GHIS 2026
GHIS 2026Human models. New partnerships.
Hong Kong
Hong Kong
GHIS 2026: Human models, new partnerships
Human-microenvironment models for target discovery, drug evaluation and collaborative development.
Read more ↗WUXI · SCIENTIFIC EXCHANGE
Human organoids & functional genomics
Wei He, PhD
© TRiCBIOWuxi, China
Human organoids & functional genomics in Wuxi
Exploring human organoids across disease modeling, target discovery and drug evaluation.
Read more ↗Project inquiry
Discuss your organoid study
Tell us your study goal and the samples or candidates you have. Our scientists will discuss models, assays, deliverables and project planning with you.